FN2 Earnings Intelligence
Abbott Laboratories financials
Abbott Laboratories (ABT) financial statements and key operating metrics from FN2 Research.
Key Stats
USD in millions, except per-share values and percentages.
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2024 | 12/31/2025 | 12/31/2026 est. | 12/31/2027 est. |
|---|---|---|---|---|---|---|---|
| Market Cap | - | - | - | - | - | - | - |
| - Cash | $9,799 | $9,882 | $6,896 | $7,616 | $8,522 | - | - |
| + Debt | $17,296 | $14,522 | $13,599 | - | - | - | - |
| Enterprise Value | - | - | - | - | - | - | - |
| Revenue | $43,075 | $43,653 | $40,109 | $41,950 | $44,328 | $50,290.9 | $54,680.8 |
| % Growth | 24.5% | 1.3% | -8.1% | 4.6% | 5.7% | 13.5% | 8.7% |
| Gross Profit | $24,538 | $24,511 | $22,134 | $23,244 | $25,009 | - | - |
| % Margin | 57.0% | 56.1% | 55.2% | 55.4% | 56.4% | - | - |
| EBITDA | $9,916 | $9,616 | $7,755 | $8,165 | $9,487 | - | - |
| % Margin | 23.0% | 22.0% | 19.3% | 19.5% | 21.4% | - | - |
| Net Income | $7,071 | $6,933 | $5,723 | $13,402 | $6,524 | - | - |
| % Margin | 16.4% | 15.9% | 14.3% | 31.9% | 14.7% | - | - |
| Diluted EPS | $3.94 | $3.91 | $3.26 | $7.64 | $3.72 | $5.51 | $6.06 |
| % Growth | 57.6% | -0.8% | -16.6% | 134.4% | -51.3% | 48.2% | 10.0% |
| Operating Cash Flow | $10,533 | $9,581 | $7,261 | $8,558 | $9,566 | - | - |
| CapEx | $1,885 | $1,777 | $2,202 | $2,207 | $2,171 | - | - |
| Free Cash Flow | $8,648 | $7,804 | $5,059 | $6,351 | $7,395 | - | - |
Historical market capitalization is not persisted, so Market Cap and Enterprise Value remain unavailable rather than mixing today's market value into prior periods.
Income Statement
USD in millions, except per-share values and percentages.
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2024 | 12/31/2025 | 12/31/2026 est. | 12/31/2027 est. |
|---|---|---|---|---|---|---|---|
| Revenue | $43,075 | $43,653 | $40,109 | $41,950 | $44,328 | $50,290.9 | $54,680.8 |
| Gross Profit | $24,538 | $24,511 | $22,134 | $23,244 | $25,009 | - | - |
| EBITDA | $9,916 | $9,616 | $7,755 | $8,165 | $9,487 | - | - |
| Net Income | $7,071 | $6,933 | $5,723 | $13,402 | $6,524 | - | - |
| Diluted EPS | $3.94 | $3.91 | $3.26 | $7.64 | $3.72 | $5.51 | $6.06 |
Balance Sheet
USD in millions, except per-share values and percentages.
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2024 | 12/31/2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $9,799 | $9,882 | $6,896 | $7,616 | $8,522 |
| Short-term Debt | $0 | $0 | $0 | - | - |
| Long-term Debt | $17,296 | $14,522 | $13,599 | $12,625 | $9,896 |
| Total Debt | $17,296 | $14,522 | $13,599 | - | - |
Cash Flow
USD in millions, except per-share values and percentages.
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2024 | 12/31/2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | $10,533 | $9,581 | $7,261 | $8,558 | $9,566 |
| Capital Expenditure | $1,885 | $1,777 | $2,202 | $2,207 | $2,171 |
| Free Cash Flow | $8,648 | $7,804 | $5,059 | $6,351 | $7,395 |
Ratios
USD in millions, except per-share values and percentages.
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2024 | 12/31/2025 |
|---|---|---|---|---|---|
| Revenue Growth | 24.5% | 1.3% | -8.1% | 4.6% | 5.7% |
| Gross Margin | 57.0% | 56.1% | 55.2% | 55.4% | 56.4% |
| EBITDA Margin | 23.0% | 22.0% | 19.3% | 19.5% | 21.4% |
| Net Margin | 16.4% | 15.9% | 14.3% | 31.9% | 14.7% |
| FCF Margin | 20.1% | 17.9% | 12.6% | 15.1% | 16.7% |
| Diluted EPS Growth | 57.6% | -0.8% | -16.6% | 134.4% | -51.3% |